Literature DB >> 16918567

Frequency and cost of actinic keratosis treatment.

Lindsey Warino1, Mark Tusa, Fabian Camacho, Hoa Teuschler, Alan B Fleischer, Steven R Feldman.   

Abstract

BACKGROUND: Actinic keratosis (AK) is a common lesion with its highest incidence in the aged population. Although treatment strategies for AK have continued to develop, the cost of such treatments has not been recently investigated.
PURPOSE: The purpose of this article is to determine the frequency of visits for AK, the methods used to treat AK, and the cost of the treatments used annually.
METHODS: Data from the Medicare Current Beneficiary Survey and National Ambulatory Medical Care Survey were used to determine the frequency of office visits for AK and the frequency of destructive procedures and topical treatment of AK. Medicare reimbursement rates were used to estimate the cost of the procedures performed. Costs of medications were based on published wholesale costs.
RESULTS: There are an estimated 5.2 million AK visits annually, 60% of which are made by the Medicare population. A total of Dollars 920 million was spent on the treatment of AK annually, 6% being spent on topical therapy, 43% on office visits, and 51% on destructive procedures.
CONCLUSIONS: Even though new topical therapies are evolving for the treatment of AK, destructive procedures remain the standard of care when considering frequency of use, efficacy, and cost control.

Entities:  

Mesh:

Year:  2006        PMID: 16918567     DOI: 10.1111/j.1524-4725.2006.32228.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  31 in total

1.  Actinic keratoses: a comprehensive update.

Authors:  Sherrif F Ibrahim; Marc D Brown
Journal:  J Clin Aesthet Dermatol       Date:  2009-07

2.  Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer.

Authors:  Joel L Cohen
Journal:  J Clin Aesthet Dermatol       Date:  2010-06

3.  Functional protein pathway activation mapping of the progression of normal skin to squamous cell carcinoma.

Authors:  Janine G Einspahr; Valerie Calvert; David S Alberts; Clara Curiel-Lewandrowski; James Warneke; Robert Krouse; Steven P Stratton; Lance Liotta; Caterina Longo; Giovanni Pellacani; Giovanni Pellicani; Anil Prasad; Paul Sagerman; Yira Bermudez; Jianghong Deng; G Timothy Bowden; Emanuel F Petricoin
Journal:  Cancer Prev Res (Phila)       Date:  2012-03

4.  A real-world, community-based cohort study comparing the effectiveness of topical fluorouracil versus topical imiquimod for the treatment of actinic keratosis.

Authors:  Romain Neugebauer; Katherine A Levandoski; Zheng Zhu; Monica Sokil; Mary-Margaret Chren; Gary D Friedman; Maryam M Asgari
Journal:  J Am Acad Dermatol       Date:  2017-12-24       Impact factor: 11.527

5.  Pharmacoeconomy of drugs used in the treatment of actinic keratoses.

Authors:  S Nisticò; V Torchia; M Gliozzi; U Bottoni; E Del Duca; C Muscoli
Journal:  Int J Immunopathol Pharmacol       Date:  2016-05-11       Impact factor: 3.219

6.  Evaluation of the prognostic significance of follicular extension in actinic keratoses.

Authors:  Shaily Pandey; Stephen E Mercer; Kai Dallas; Patrick O Emanuel; Gary Goldenberg
Journal:  J Clin Aesthet Dermatol       Date:  2012-04

Review 7.  Interventions for actinic keratoses.

Authors:  Aditya K Gupta; Maryse Paquet; Elmer Villanueva; William Brintnell
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

8.  Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: A cohort study.

Authors:  Romain Neugebauer; Katherine A Su; Zheng Zhu; Monica Sokil; Mary-Margaret Chren; Gary D Friedman; Maryam M Asgari
Journal:  J Am Acad Dermatol       Date:  2018-11-17       Impact factor: 11.527

9.  Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin.

Authors:  Susan J Huang; Dirkjan Hijnen; George F Murphy; Thomas S Kupper; Adam W Calarese; Ilse G Mollet; Carl F Schanbacher; Danielle M Miller; Chrysalyne D Schmults; Rachael A Clark
Journal:  J Invest Dermatol       Date:  2009-06-11       Impact factor: 8.551

Review 10.  Molecular cancer prevention: Current status and future directions.

Authors:  Karen Colbert Maresso; Kenneth Y Tsai; Powel H Brown; Eva Szabo; Scott Lippman; Ernest T Hawk
Journal:  CA Cancer J Clin       Date:  2015-08-18       Impact factor: 508.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.